Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024.

IF 17.3 1区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

MMWR. Morbidity and mortality weekly report Pub Date : 2025-08-21 DOI:10.15585/mmwr.mm7431a3

Ellen O Boundy, Hannah Fast, Tara C Jatlaoui, Hilda Razzaghi, LaTreace Harris, Kimberly Nguyen, Jamie Mells, Georgina Peacock, Carla L Black

{"title":"Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024.","authors":"Ellen O Boundy, Hannah Fast, Tara C Jatlaoui, Hilda Razzaghi, LaTreace Harris, Kimberly Nguyen, Jamie Mells, Georgina Peacock, Carla L Black","doi":"10.15585/mmwr.mm7431a3","DOIUrl":null,"url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the United States. A new RSV monoclonal antibody (nirsevimab) for infants and an RSV vaccine for pregnant women were recommended by the Advisory Committee on Immunization Practices in August and September 2023, respectively, to protect infants against RSV infection. Sufficient data have become available to allow estimates of infant RSV immunization coverage through administration of these products. Among infants born during October 2023-March 2024, infant RSV immunization coverage was estimated by summing the total number of infants who received nirsevimab and the number of women of childbearing age who received RSV vaccine, as reported to immunization information systems (IISs) in 33 U.S. states and the District of Columbia (DC), and dividing by the total number of live births, obtained from CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) natality data. Across 33 states and DC, an estimated 29% of infants born during October 2023-March 2024 were immunized against RSV during the 2023-24 respiratory virus season, including 19% through infant receipt of nirsevimab and 10% through maternal RSV vaccination. Infant RSV immunization coverage through nirsevimab or maternal vaccination ranged from an estimated 11% to 53% by state. Among infants who received nirsevimab, 38% received it within the first week of life (0-6 days after birth). Continued efforts are needed to increase RSV immunization coverage among infants and pregnant women.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 31","pages":"484-489"},"PeriodicalIF":17.3000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370014/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7431a3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the United States. A new RSV monoclonal antibody (nirsevimab) for infants and an RSV vaccine for pregnant women were recommended by the Advisory Committee on Immunization Practices in August and September 2023, respectively, to protect infants against RSV infection. Sufficient data have become available to allow estimates of infant RSV immunization coverage through administration of these products. Among infants born during October 2023-March 2024, infant RSV immunization coverage was estimated by summing the total number of infants who received nirsevimab and the number of women of childbearing age who received RSV vaccine, as reported to immunization information systems (IISs) in 33 U.S. states and the District of Columbia (DC), and dividing by the total number of live births, obtained from CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) natality data. Across 33 states and DC, an estimated 29% of infants born during October 2023-March 2024 were immunized against RSV during the 2023-24 respiratory virus season, including 19% through infant receipt of nirsevimab and 10% through maternal RSV vaccination. Infant RSV immunization coverage through nirsevimab or maternal vaccination ranged from an estimated 11% to 53% by state. Among infants who received nirsevimab, 38% received it within the first week of life (0-6 days after birth). Continued efforts are needed to increase RSV immunization coverage among infants and pregnant women.

Abstract Image

查看原文本刊更多论文

通过接受尼塞维单抗单克隆抗体或母亲接种疫苗，婴儿呼吸道合胞病毒免疫覆盖率-美国，2023年10月至2024年3月

呼吸道合胞病毒（RSV）是美国婴儿住院的主要原因。2023年8月和9月，免疫实践咨询委员会分别推荐了一种用于婴儿的新的RSV单克隆抗体（nirsevimab）和用于孕妇的RSV疫苗，以保护婴儿免受RSV感染。已有足够的数据可用于通过使用这些产品来估计婴儿呼吸道合胞病毒免疫接种覆盖率。在2023年10月至2024年3月期间出生的婴儿中，通过将美国33个州和哥伦比亚特区免疫信息系统（IISs）报告的接种nirsevimab的婴儿总数和接种RSV疫苗的育龄妇女人数相加，并除以从CDC广泛在线流行病学研究数据（WONDER）出生数据中获得的活产总数，来估计婴儿RSV免疫覆盖率。在33个州和哥伦比亚特区，2023年10月至2024年3月期间出生的婴儿中，估计有29%在2023年至2024年呼吸道病毒季节期间接种了RSV疫苗，其中19%通过婴儿接种了尼塞维单抗，10%通过母亲接种了RSV疫苗。各州通过尼塞维单抗或母亲疫苗接种的婴儿呼吸道合胞病毒免疫覆盖率估计在11%至53%之间。在接受nirsevimab治疗的婴儿中，38%在出生后第一周（出生后0-6天）接受了治疗。需要继续努力提高婴儿和孕妇的呼吸道合胞病毒免疫覆盖率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MMWR. Morbidity and mortality weekly report PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -

CiteScore

65.40

自引率

0.90%

发文量

309

期刊介绍： The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC). Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.